XELJANZ (tofacitinib citrate)
INFLAMMATORY BOWEL AGENTS · ULCERATIVE COLITIS ·+4
Parke-Davis Pfizer
Drug class
Inflammatory Bowel Agents
Inflammatory bowel agents represent a broad therapeutic and formulary category comprising pharmacologically diverse medications used to treat chronic inflammatory diseases of the gastrointestinal tract. Read more about Inflammatory Bowel Agents
230 drugs in this class 81 manufacturers
Drugs in Inflammatory Bowel Agents
SIMPONI ARIA (golimumab)
INFLAMMATORY BOWEL AGENTS · PSORIATIC ARTHRITIS ·+3
JANSSEN BIOTECH, Inc.
ENTYVIO (vedolizumab)
INFLAMMATORY BOWEL AGENTS · CROHN'S DISEASE ·+1
Takeda Pharmaceuticals America
MESALAMINE (mesalamine with cleansing wipes)
INFLAMMATORY BOWEL AGENTS · ULCERATIVE PROCTITIS ·+2
WALLACE PHARMAC
HUMIRA PEDIATRIC CROHN'S (adalimumab)
ANTIPSORIATICS · CROHN'S DISEASE ·+8
ABBOTT
HUMIRA PEDIATRIC CROHN'S (adalimumab)
ANTIPSORIATICS · CROHN'S DISEASE ·+8
ABBOTT
MESALAMINE
INFLAMMATORY BOWEL AGENTS · ULCERATIVE PROCTITIS ·+2
WALLACE PHARMAC
XELJANZ XR (tofacitinib citrate)
INFLAMMATORY BOWEL AGENTS · ULCERATIVE COLITIS ·+3
Parke-Davis Pfizer
MESALAMINE
INFLAMMATORY BOWEL AGENTS · ULCERATIVE PROCTITIS ·+2
ANI PHARMACEUTI
Filter & compare in the drug finder →
Opens the drug finder with Inflammatory Bowel Agents preselected. Add indication or manufacturer filters there.
Inflammatory bowel agents represent a broad therapeutic and formulary category comprising pharmacologically diverse medications used to treat chronic inflammatory diseases of the gastrointestinal tract.
Rather than operating via a single mechanism of action, medications in this grouping reduce mucosal inflammation and modulate aberrant immune responses through local prostaglandin and leukotriene inhibition, broad immunosuppression, cytokine antagonism, or targeted cellular signaling blockade.
Their primary therapeutic role is to induce and maintain clinical and endoscopic remission in patients with ulcerative colitis and Crohn's disease.
-
fda.gov
Inflammatory bowel agents represent a broad therapeutic and formulary category comprising pharmacologically diverse medications used to treat chronic inflammatory diseases of the gastrointestinal tract
-
nih.gov
Inflammatory bowel agents represent a broad therapeutic and formulary category comprising pharmacologically diverse medications used to treat chronic inflammatory diseases of the gastrointestinal tract Rather than operating via a single mechanism of action, medications in this grouping reduce mucosal inflammation and modulate aberrant immune responses through local prostaglandin and leukotriene inhibition, broad immunosuppression, cytokine antagonism, or targeted cellular signaling blockade Thei...
-
medlineplus.gov
Rather than operating via a single mechanism of action, medications in this grouping reduce mucosal inflammation and modulate aberrant immune responses through local prostaglandin and leukotriene inhibition, broad immunosuppression, cytokine antagonism, or targeted cellular signaling blockade
-
fda.gov
Their primary therapeutic role is to induce and maintain clinical and endoscopic remission in patients with ulcerative colitis and Crohn's disease
-
nih.gov
Their primary therapeutic role is to induce and maintain clinical and endoscopic remission in patients with ulcerative colitis and Crohn's disease
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.